Document is current
Any future updates will be listed below
-
Authors
Westerback, Emily
Wilson-Robles, Heather
Bougoussa, M’hammed
Istvan, Stephanie
Stewart, Samuel
Warry, Emma
Heinz, Justin
-
Funding
Funding for this research was provided by:
Belgian Volition
- License Information
-
More Information
Article History
Received: 8 November 2024
Accepted: 23 April 2025
First Online: 17 May 2025
Declarations
:
: All experimental procedures were conducted following the relevant guidelines and regulations for the experimental research on animals. Study design was reviewed and approved by each institution’s respective IACUC. All cat owners signed a written consent form and were aware that samples were being collected for research purposes.
: Not applicable.
: Volition Veterinary Diagnostics Development LLC is a joint venture between Belgian Volition SRL and Texas A&M University. Volition America Inc, Volition Diagnostics UK Ltd, Volition Veterinary Diagnostics Development LLC and Belgian Volition SRL are subsidiaries of VolitionRx Ltd. Belgian Volition SRL has patents covering Nu.Q® technology and are developers of Nu.Q® assays. Funding for materials and some author salaries was provided by Belgian Volition SRL. HWR, acting as the Chief Medical Officer of Volition Veterinary Diagnostics Development LLC, is a part-time employee of Volition America Inc, and holds stock, stock options and Restricted Stock Units of VolitionRx Ltd.MB is an employee of Belgian Volition SRL. JAH is a paid consultant of Volition Veterinary Diagnostics Development LLC and holds stock and Restricted Stock Units of VolitionRx Ltd. Other authors have no conflicts of interest to declare.
